MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials (Q37964985)

26 August 2017

title

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials (English)

1 reference

magnetic resonance imaging

26 August 2017

0 references

0 references

5

Ludwig Kappos

1 reference

26 August 2017

1

Frederik Barkhof

1 reference

26 August 2017

3

Franz Fazekas

1 reference

26 August 2017

14

David H Miller

1 reference

26 August 2017

13

Xavier Montalban

1 reference

26 August 2017

7

Chris H Polman

1 reference

26 August 2017

Jack H Simon

2

1 reference

26 August 2017

Marco Rovaris

4

1 reference

26 August 2017

Nicola de Stefano

6

1 reference

26 August 2017

John Petkau

8

1 reference

26 August 2017

Ernst W Radue

9

1 reference

26 August 2017

Maria P Sormani

10

1 reference

26 August 2017

David K Li

11

1 reference

26 August 2017

Paul O'Connor

12

1 reference

26 August 2017

Massimo Filippi

15

1 reference

26 August 2017

language of work or name

English

0 references

publication date

6 December 2011

1 reference

26 August 2017

published in

Nature Reviews Neurology

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

13-21

1 reference

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

A controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Multiple sclerosis trial designs for the 21st century: building on recent lessons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Antibody-mediated suppression of Vbeta5.2/5.3( ) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Assessing changes in relapse rates in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

MRI--the perfect surrogate marker for multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Meta-analysis for the evaluation of potential surrogate markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

High field MRI in the diagnosis of multiple sclerosis: high field-high yield?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Improved Identification of Intracortical Lesions in Multiple Sclerosis with Phase-Sensitive Inversion Recovery in Combination with Fast Double Inversion Recovery MR Imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

The Holy Grail in diagnostic neuroradiology: 3T or 3D?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Spinal-cord MRI in multiple sclerosis: conventional and nonconventional MR techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

A nonparametric method for automatic correction of intensity nonuniformity in MRI data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

A fully automatic and robust brain MRI tissue classification method

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Advances in functional and structural MR image analysis and implementation as FSL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Incorporating domain knowledge into the fuzzy connectedness framework: application to brain lesion volume estimation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Improved detection of active multiple sclerosis lesions: 3D subtraction imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium‐enhanced MR images

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Assessing surrogates as trial endpoints using mixed models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Spinal cord atrophy and disability in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEUROL.2011.190

Evaluation of safety monitoring guidelines based on MRI lesion activity in multiple sclerosis.

31 March 2020

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium

1 reference

12 December 2020

Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials

1 reference

12 December 2020

10.1038/NRNEUROL.2011.190

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1038377997

0 references

1 reference